Alnylam Pharmaceuticals Inc (ALNY)vsBright Minds Biosciences Inc (DRUG)
ALNY
Alnylam Pharmaceuticals Inc
$286.41
-0.19%
HEALTHCARE · Cap: $37.76B
DRUG
Bright Minds Biosciences Inc
$69.00
-7.38%
HEALTHCARE · Cap: $583.72M
Smart Verdict
WallStSmart Research — data-driven comparison
ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
DRUG
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2363.38
Current Price
$286.41
$2076.97 discount
Intrinsic value data unavailable for DRUG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 35.5x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : DRUG
The strongest argument for DRUG centers on Debt/Equity, Altman Z-Score.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : DRUG
The primary concerns for DRUG are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ALNY profiles as a growth stock while DRUG is a value play — different risk/reward profiles.
ALNY carries more volatility with a beta of 0.27 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
ALNY generates stronger free cash flow (49M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (65/100 vs 28/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Bright Minds Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Bright Minds Biosciences Inc. (DRUG) is a pioneering clinical-stage biotechnology company dedicated to creating innovative therapies for central nervous system disorders, with a strong focus on mental health and pain management. Harnessing its proprietary drug development platform, Bright Minds is advancing a diverse pipeline of treatments, strategically aligned with the growing acceptance of psychedelic therapies. The company's experienced management team and extensive intellectual property portfolio position it uniquely to capitalize on the surging demand for novel mental health solutions, representing a compelling investment opportunity for institutional investors in the dynamic pharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?